Blood-brain barrier Laboratory, EA2465
Faculty Jean Perrin, Artois University
The group is recognized as world expert in the modelling of the BBB. Indeed, this team has carried out pioneering work in establishing an animal model of the BBB which has been used to investigate BBB physiology and distribution of compounds for pharmaceutical industries. New BBB models have also been used to better characterize the BBB in stroke (FP7 Eustroke and EU Joint programme). In 2013, the team set up a human in vitro model of the BBB consisting to cultivate CD34+-cells with brain pericytes which is now widely used for mechanistic studies and for permeability screenings. Currently his team is involved in 3 different Innovative Training Networks, 1 Euronanomed (DIASYN) and 1 JPCoFUND European projects. Two permanent scientists (1 professor and 1 research engineer) and 1 post-doc will be implicated in the evaluation of the effects of secretome and nanocapsules at the BBB level.
Role in the project
Function of endothelial cells and brain pericytes, BBB modelling and physiology.
Fabien Gosselet graduated in Biology and received a PhD in Cancerology (2006) from the Medicine faculty of Paris XI. He completed his education at the bloodbrain barrier laboratory (BBB-Lab), located in Lens (France), as post-doctoral fellowship. In 2008 he obtained an assistant Professor position at the BBB-Lab and is full Professor since 2016. He was the co-head of the BBB-lab from 2013 to 2014. Since 2015, he is director of the BBB-Lab. The 30 members of his lab use housemade in vitro BBB models not only for investigating BBB physiology and its role in neurodegenerative diseases (Alzheimer’s and Parkinson diseases, stroke, brain tumor metastasis,…) but also for improving drug delivery and for providing data in pharmaco-toxicological field and to pharmaceutical companies. Since its creation in 2000, the BBB-lab actively contributed to several FP6 (AcuteTox) and FP7 (Predict IV, Eustroke) programs and is currently involved in three H2020 consortia (BtRAIN, In3, Nanostem) and two European projects (DiaSyn and SnowBall). In 2014, the BBB-lab developed and patented a human in vitro BBB models consisting to co-cultivate human umbilical cord blood stem cells with brain pericytes. This model is now transferred into 25 European Labs.
Scientific production : 45 research articles and 11 review articles in international peer reviewed journals, 2 editorial letters, 2 book chapters. Participation in more than 50 international and national conferences among which 12 as invited speaker. Editorial board of 4 journals. More than 100 reviewing for peer-reviewed journals, associations and for national/international agencies.
Bibliometric data: 1200 citations, H-factor=21 Other: Participation in more than 15 National and collaborative International research projects, 7 as IP . Contracts with private companies and consultings. Supervision of 7 PhD Theses (5 finalized).
Rodrigo Azevedo Loiola
Rodrigo Loiola finished his bachelor’s degree in Nursing at Universidade de São Paulo (Brazil, 2004). Afterward, he concluded his master degree in Pharmacology (Universidade de São Paulo, Brazil – 2007) and Ph.D. in Molecular Biology (Universidade Federal de São Paulo, Brazil – 2011). Since then, he was awarded two postdoctoral fellowships from the Brazilian government to carry on his studies on inflammation and vascular system. Firstly, he investigated the effects of pollutants exposure on the immune system and its relation with genesis and/or progression of type 2 diabetes mellitus (T2DM), under the supervision of Dr. Sandra Farsky (Universidade de São Paulo, Brazil). In parallel, he participated on projects evaluating the suitability of magnetic nanoparticles as contrast agents for magnetic resonance imaging, and the therapeutical effect of lipid nanocapsules on the treatment of glioblastoma (2012-2015). More recently, he was awarded a fellowship to investigate the effects of T2DM and Multiple Sclerosis on the blood-brain barrier at William Harvey Research Institute (London, UK), under the supervision of Dr. Egle Solito (2015-2017). In September 2018, he joined LBHE at Jean Perrin Faculty of Science to work in the MAGBBRIS project.
List of relevant publications
1: Versele R, Corsi M, Fuso A, Sevin E, Businaro R, Gosselet F, Fenart L, Candela P. Ketone Bodies Promote Amyloid-β(1-40) Clearance in a Human in Vitro Blood-Brain Barrier Model. Int J Mol Sci. 2020 Jan 31;21(3). pii: E934. doi: 10.3390/ijms21030934. PubMed PMID: 32023814; PubMed Central PMCID: PMC7037612.
2: Mehra A, Dehouck L, Vandenhaute E, Fatar M, Fenart L, Gosselet F. A High Output Method to Isolate Cerebral Pericytes from Mouse. J Vis Exp. 2020 Jan 14;(155). doi: 10.3791/60588. PubMed PMID: 32009659.
3: Sevin E, Dehouck L, Versele R, Culot M, Gosselet F. A Miniaturized Pump Out Method for Characterizing Molecule Interaction with ABC Transporters. Int J Mol Sci. 2019 Nov 6;20(22). pii: E5529. doi: 10.3390/ijms20225529. PubMed PMID: 31698745; PubMed Central PMCID: PMC6888615.
4: Mossu A, Rosito M, Khire T, Li Chung H, Nishihara H, Gruber I, Luke E, Dehouck L, Sallusto F, Gosselet F, McGrath JL, Engelhardt B. A silicon nanomembrane platform for the visualization of immune cell trafficking across the human blood-brain barrier under flow. J Cereb Blood Flow Metab. 2019 Mar;39(3):395-410. Doi: 10.1177/0271678X18820584. Epub 2018 Dec 19. PubMed PMID: 30565961; PubMed Central PMCID: PMC6421249.
5: Lamartinière Y, Boucau MC, Dehouck L, Krohn M, Pahnke J, Candela P, Gosselet F, Fenart L. ABCA7 Downregulation Modifies Cellular Cholesterol Homeostasis and
Decreases Amyloid-β Peptide Efflux in an in vitro Model of the Blood-Brain Barrier. J Alzheimers Dis. 2018;64(4):1195-1211. doi: 10.3233/JAD-170883. PubMed PMID: 30010117.